Molecular analysis of p53 tumor-suppressor gene and microsatellites in preneoplastic and neoplastic lesions of the colon and esophagus.

Mutations in exons 4-8 of the p53 gene by the PCR-SSCP analysis in preneoplastic and neoplastic lesions of the colon (n=11) and esophagus (n=18) were screened. p53 overexpression by immunohistochemistry in 11 colonic lesions and 13 microsatellites, in all the patients (n=29), were also studied. A positive result concordancy between the three techniques was found in 1 adenoma and 2 adenocarcinomas of the colon, each with loss of heterozygocity of microsatellites. Metaplastic lesions of esophagus showed biallelic mutations and low frequency of microsatellite alterations. The relationship between genetic alterations in p53, microsatellites and type of colon and esophageal lesions is discussed.     

The Enantioselective Binding of Mefloquine Enantiomers to P-glycoprotein Determined Using An Immobilized P-glycoprotein Liquid Chromatographic Stationary Phase

Pharmaceutical Research -     

La gestion des affects dans la relation thérapeutique chez le patient schizophrène

This article studies schizophrenic patient's affective conflict by non-integrated ambivalence and absence of symbolisation of affect. Through the meet with a psychotic patient, the authors show that evolution of therapeutic relation is on a par with affect-representation link and its expression in therapy. The authors differentiate processes, which are involved in affect-representation link ; ones concern on representation (in particular déscénarisation and démétaphorisation), others concern on affect, as “thinging” of affects and external deposit of affect. The term of “insulating split”, a form of psychotic insulation, is used to describe this process.     

Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer

Introduction

Partner and localizer of BRCA2 (PALB2) is essential for homologous recombination repair. We examined mRNA levels of DNA repair genes, including partner and localizer of BRCA2 gene (PALB2), ring finger protein 8 gene (RNF8), replication timing regulatory factor 1 gene (RIF1), ATM serine/threonine kinase gene (ATM), and tumor protein p53 binding protein 1 gene (53BP1) as predictive biomarkers for cisplatin-docetaxel in the European phase III BRCA1, DNA repair associated (BRCA1)–receptor-associated protein 80 (RAP80) expression customization (BREC) phase III clinical trial (ClinicalTrials.gov identifier NCT00617656).